Adding first-line PD-1 inhibition to anti-VEGF and XELOX in pMMR metastatic colorectal cancer: Steppingstones, stumbling blocks, and next phase

Torhild Veen; Kjetil Søreide

doi:10.1016/j.medj.2024.06.006

Adding first-line PD-1 inhibition to anti-VEGF and XELOX in pMMR metastatic colorectal cancer: Steppingstones, stumbling blocks, and next phase

Med. 2024 Sep 13;5(9):1041-1043. doi: 10.1016/j.medj.2024.06.006. Epub 2024 Jul 3.

Authors

Torhild Veen¹, Kjetil Søreide²

Affiliations

¹ Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway; Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway.
² Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway; Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway. Electronic address: [email protected].

PMID: 38964335
DOI: 10.1016/j.medj.2024.06.006

Abstract

In the randomized, double-blind, multicenter study by Wang et al.,¹ the addition of serplulimab (a PD-1 antibody) to anti-VEGF (HLX04; a bevacizumab biosimilar) together with chemotherapy (XELOX) was deemed to be tolerable and safe and may improve progression-free survival. However, even if adverse events were comparable, oncological endpoints including survival need to be confirmed in the next phase 3 study.

Keywords: Translation to patients.

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / pharmacology
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bevacizumab / administration & dosage
Bevacizumab / pharmacology
Bevacizumab / therapeutic use
Capecitabine* / administration & dosage
Capecitabine* / therapeutic use
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Deoxycytidine / therapeutic use
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Oxaloacetates
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Progression-Free Survival
Vascular Endothelial Growth Factor A* / antagonists & inhibitors
Vascular Endothelial Growth Factor A* / immunology

Substances

Capecitabine
Vascular Endothelial Growth Factor A
Oxaloacetates
Bevacizumab
Programmed Cell Death 1 Receptor
Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized
Deoxycytidine

Supplementary concepts

XELOX